PE20231566A1 - Agonistas del receptor npy2 solubles - Google Patents
Agonistas del receptor npy2 solublesInfo
- Publication number
- PE20231566A1 PE20231566A1 PE2023000199A PE2023000199A PE20231566A1 PE 20231566 A1 PE20231566 A1 PE 20231566A1 PE 2023000199 A PE2023000199 A PE 2023000199A PE 2023000199 A PE2023000199 A PE 2023000199A PE 20231566 A1 PE20231566 A1 PE 20231566A1
- Authority
- PE
- Peru
- Prior art keywords
- soluble
- receptor agonists
- analogues
- npy2 receptor
- npy2
- Prior art date
Links
- 102000029748 Neuropeptide Y2 receptor Human genes 0.000 title 1
- 108010089579 neuropeptide Y2 receptor Proteins 0.000 title 1
- 239000000018 receptor agonist Substances 0.000 title 1
- 229940044601 receptor agonist Drugs 0.000 title 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 abstract 1
- 239000004472 Lysine Substances 0.000 abstract 1
- 235000004279 alanine Nutrition 0.000 abstract 1
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 abstract 1
- 210000004899 c-terminal region Anatomy 0.000 abstract 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Endocrinology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- General Chemical & Material Sciences (AREA)
- Toxicology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Child & Adolescent Psychology (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
Abstract
La invencion se refiere a analogos de PYY que tienen alanina en la posicion 4, lisina en la posicion 7, QRY como el extremo del terminal C y un grupo de prolongacion de semivida. Los analogos de la invencion son solubles a alrededor de pH 6 y 7. La invencion tambien se refiere a composiciones farmaceuticas que comprenden tales analogos de PYY y al uso medico de los analogos
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP20189966 | 2020-08-07 | ||
| PCT/EP2021/071873 WO2022029231A1 (en) | 2020-08-07 | 2021-08-05 | Soluble npy2 receptor agonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20231566A1 true PE20231566A1 (es) | 2023-10-04 |
Family
ID=71995807
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2023000199A PE20231566A1 (es) | 2020-08-07 | 2021-08-05 | Agonistas del receptor npy2 solubles |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US20220041678A1 (es) |
| EP (1) | EP4192853A1 (es) |
| JP (1) | JP2023537036A (es) |
| KR (1) | KR20230045088A (es) |
| CN (1) | CN116171282A (es) |
| AR (1) | AR123174A1 (es) |
| AU (1) | AU2021322137A1 (es) |
| BR (1) | BR112022025623A2 (es) |
| CA (1) | CA3185637A1 (es) |
| CL (1) | CL2023000357A1 (es) |
| CO (1) | CO2023000637A2 (es) |
| CR (1) | CR20230074A (es) |
| DO (1) | DOP2023000010A (es) |
| EC (1) | ECSP23003649A (es) |
| IL (1) | IL300239A (es) |
| MX (1) | MX2023001532A (es) |
| PE (1) | PE20231566A1 (es) |
| TW (1) | TW202222335A (es) |
| WO (1) | WO2022029231A1 (es) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2022210988B9 (en) | 2021-01-20 | 2024-02-22 | Viking Therapeutics, Inc. | Compositions and methods for the treatment of metabolic and liver disorders |
| US20240091318A1 (en) | 2022-08-18 | 2024-03-21 | Boehringer Ingelheim International Gmbh | Combination therapy comprising long acting glp-1/glucagon and npy2 receptor agonists |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2007525495A (ja) | 2004-02-11 | 2007-09-06 | アミリン・ファーマシューティカルズ，インコーポレイテッド | 選択可能な特性を有するハイブリッドポリペプチド |
| BRPI0518559A2 (pt) | 2004-12-13 | 2008-11-25 | Amylin Pharmaceuticals Inc | motivos da famÍlia do polipetÍdeo pancreÁtico, polipeptÍdeos e mÉtodos compreendendo os mesmos |
| AU2008216265B2 (en) | 2007-02-15 | 2014-04-03 | Indiana University Research And Technology Corporation | Glucagon/GLP-1 receptor co-agonists |
| WO2008152403A1 (en) | 2007-06-15 | 2008-12-18 | Zealand Pharma A/S | Glucagon analogues |
| CN101939022A (zh) | 2007-11-14 | 2011-01-05 | 安米林药品公司 | 治疗肥胖以及肥胖相关疾病和病症的方法 |
| WO2010070252A1 (en) | 2008-12-15 | 2010-06-24 | Zealand Pharma A/S | Glucagon analogues |
| UA104605C2 (uk) | 2008-12-15 | 2014-02-25 | Зіленд Фарма А/С | Аналоги глюкагону |
| CN102282166B (zh) | 2008-12-15 | 2015-04-01 | 西兰制药公司 | 胰高血糖素类似物 |
| KR101593406B1 (ko) | 2008-12-15 | 2016-02-12 | 질랜드 파마 에이/에스 | 글루카곤 유사체 |
| PL2454282T3 (pl) | 2009-07-13 | 2015-08-31 | Zealand Pharma As | Acylowane analogi glukagonu |
| EP2477643A1 (en) | 2009-09-18 | 2012-07-25 | Novo Nordisk A/S | Long-acting y2 receptor agonists |
| US20130096055A1 (en) | 2009-11-13 | 2013-04-18 | Novo Nordisk A/S | Long-acting y2 receptor agonists |
| UY33462A (es) | 2010-06-23 | 2012-01-31 | Zealand Pharma As | Analogos de glucagon |
| JP6023048B2 (ja) | 2010-06-24 | 2016-11-09 | ジーランド ファーマ アクティーゼルスカブ | グルカゴン類似体 |
| PL2718316T3 (pl) | 2011-06-10 | 2020-06-29 | Novo Nordisk A/S | Polipeptydy |
| KR20140114845A (ko) | 2011-12-23 | 2014-09-29 | 질랜드 파마 에이/에스 | 글루카곤 유사체 |
| KR102184241B1 (ko) | 2012-05-03 | 2020-12-01 | 질랜드 파마 에이/에스 | Ｇｉｐ-ｇｌｐ-1 이원 작용제 화합물 및 방법 |
| TWI608013B (zh) | 2012-09-17 | 2017-12-11 | 西蘭製藥公司 | 升糖素類似物 |
| ES2732291T3 (es) | 2013-05-02 | 2019-11-21 | Glaxosmithkline Ip Dev Ltd | Péptidos terapéuticos |
| AR097701A1 (es) | 2013-09-19 | 2016-04-13 | Zealand Pharma As | Análogos de amilina |
| EP3057984B1 (en) | 2013-10-17 | 2018-07-11 | Zealand Pharma A/S | Acylated glucagon analogues |
| US9988429B2 (en) | 2013-10-17 | 2018-06-05 | Zealand Pharma A/S | Glucagon analogues |
| TR201902516T4 (tr) | 2013-11-06 | 2019-03-21 | Zealand Pharma As | Glukagon-glp-1-gıp üçlü agonist bileşikleri. |
| MX2016006049A (es) | 2013-11-14 | 2016-08-12 | Keybioscience Ag | Mimeticos de calcitonina para tratar enfermedades y trastornos. |
| RS59026B1 (sr) | 2013-11-15 | 2019-08-30 | Novo Nordisk As | Selektivna pyy jedinjenja i njihova upotreba |
| JP6769984B2 (ja) | 2015-03-18 | 2020-10-14 | ジーランド ファーマ アクティーゼルスカブ | アミリン類似体 |
| MX2017012864A (es) | 2015-04-16 | 2018-06-12 | Zealand Pharma As | Analogo acilado del glucagon. |
| TWI694082B (zh) | 2015-06-12 | 2020-05-21 | 丹麥商諾佛 儂迪克股份有限公司 | 選擇性ｐｙｙ化合物及其用途 |
| WO2016198624A1 (en) | 2015-06-12 | 2016-12-15 | Sanofi | Exendin-4 derivatives as trigonal glp-1/glucagon/gip receptor agonists |
| HRP20220995T1 (hr) | 2015-12-31 | 2022-11-11 | Hanmi Pharm. Co., Ltd. | Trostruki aktivator koji aktivira glukagonski, glp-1 i gip receptore |
| TWI784968B (zh) | 2016-09-09 | 2022-12-01 | 丹麥商西蘭製藥公司 | 澱粉素類似物 |
| JOP20190097A1 (ar) | 2016-10-27 | 2019-04-28 | Janssen Pharmaceutica Nv | الجلوبولينات المناعية واستخداماتها |
| AR110300A1 (es) | 2016-12-02 | 2019-03-13 | Sanofi Sa | Compuestos como agonistas peptídicos trigonales de los receptores de glp1 / glucagón / gip |
| AR110301A1 (es) | 2016-12-02 | 2019-03-13 | Sanofi Sa | Compuestos como agonistas peptídicos de receptores de glp1 / glucagón / gip |
| GB201704429D0 (en) | 2017-03-21 | 2017-05-03 | Keybioscience Ag | Calcitonin mimetics for treating diseases and disorders |
| TWI749381B (zh) | 2018-11-01 | 2021-12-11 | 美商美國禮來大藥廠 | 蛋白質酪胺酸-酪胺酸類似物及其使用方法 |
| JP2023500895A (ja) * | 2019-11-11 | 2023-01-11 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｎｐｙ２受容体アゴニスト |
-
2021
- 2021-08-05 KR KR1020237008139A patent/KR20230045088A/ko unknown
- 2021-08-05 CA CA3185637A patent/CA3185637A1/en active Pending
- 2021-08-05 PE PE2023000199A patent/PE20231566A1/es unknown
- 2021-08-05 CR CR20230074A patent/CR20230074A/es unknown
- 2021-08-05 BR BR112022025623A patent/BR112022025623A2/pt unknown
- 2021-08-05 IL IL300239A patent/IL300239A/en unknown
- 2021-08-05 MX MX2023001532A patent/MX2023001532A/es unknown
- 2021-08-05 AU AU2021322137A patent/AU2021322137A1/en active Pending
- 2021-08-05 CN CN202180057489.4A patent/CN116171282A/zh active Pending
- 2021-08-05 JP JP2023508079A patent/JP2023537036A/ja active Pending
- 2021-08-05 US US17/394,522 patent/US20220041678A1/en active Pending
- 2021-08-05 WO PCT/EP2021/071873 patent/WO2022029231A1/en active Application Filing
- 2021-08-05 EP EP21763019.3A patent/EP4192853A1/en active Pending
- 2021-08-06 TW TW110129087A patent/TW202222335A/zh unknown
- 2021-08-06 AR ARP210102204A patent/AR123174A1/es unknown
-
2023
- 2023-01-17 EC ECSENADI20233649A patent/ECSP23003649A/es unknown
- 2023-01-20 CO CONC2023/0000637A patent/CO2023000637A2/es unknown
- 2023-01-20 DO DO2023000010A patent/DOP2023000010A/es unknown
- 2023-02-03 CL CL2023000357A patent/CL2023000357A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2023537036A (ja) | 2023-08-30 |
| AU2021322137A1 (en) | 2023-01-19 |
| WO2022029231A1 (en) | 2022-02-10 |
| CN116171282A (zh) | 2023-05-26 |
| MX2023001532A (es) | 2023-03-08 |
| US20220041678A1 (en) | 2022-02-10 |
| IL300239A (en) | 2023-03-01 |
| EP4192853A1 (en) | 2023-06-14 |
| CA3185637A1 (en) | 2022-02-10 |
| AR123174A1 (es) | 2022-11-02 |
| CO2023000637A2 (es) | 2023-01-26 |
| BR112022025623A2 (pt) | 2023-03-07 |
| ECSP23003649A (es) | 2023-03-31 |
| TW202222335A (zh) | 2022-06-16 |
| KR20230045088A (ko) | 2023-04-04 |
| DOP2023000010A (es) | 2023-02-15 |
| CL2023000357A1 (es) | 2023-09-29 |
| CR20230074A (es) | 2023-04-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2023000357A1 (es) | Agonistas del receptor npy2 solubles | |
| ECSP22037660A (es) | Agonistas del receptor npy2 | |
| CL2018003319A1 (es) | Compuestos de mic-1 y usos de estos. | |
| EA202192588A1 (ru) | Фармацевтическая композиция, включающая вариант ph20 гиалуронидазы человека, и лекарственное средство для подкожного введения | |
| BR112017025108A2 (pt) | compostos seletivos de pyy e usos dos mesmos | |
| CL2019003441A1 (es) | Puestos de mic-1 y usos de estos. | |
| NZ743487A (en) | Controlled-release cnp agonists with increased nep stability | |
| NZ743488A (en) | Controlled-release cnp agonists with low initial npr-b activity | |
| NZ743489A (en) | Controlled-release cnp agonists with low npr-c binding | |
| BR112022002720A2 (pt) | Formulações de conjugados de benzazepinas e usos das mesmas | |
| EA202091095A1 (ru) | Пероральная доставка пептидных аналогов glp-1 | |
| PE20211466A1 (es) | Analogos de proteina tirosina-tirosina y metodos de uso de esta | |
| CL2021000938A1 (es) | Composiciones estables de semaglutida y usos de las mismas | |
| NI202000071A (es) | Conjugados del péptido de fusión péptido similar al glucagón 1 (glp-1) acoplado al péptido tirosina tirosina cíclico y usos de estos | |
| PE20211772A1 (es) | Inmunoterapia con peptidos restringidos a b 08 y una combinacion de peptidos contra el cancer y metodos relacionados | |
| MX2020003697A (es) | Formulaciones farmaceuticas que comprenden un agonista del receptor opioide como ingredientes activos, metodos de fabricacion y usos terapeuticos de las mismas. | |
| BR112022006297A2 (pt) | Agonistas de receptor de npy2 | |
| MX2016004660A (es) | Composiciones de peptido novedosas. | |
| EA202192475A1 (ru) | Способ получения стабильных пептидных составов | |
| AR113966A1 (es) | LIGANDOS PÉPTIDOS BICÍCLICOS ESPECÍFICOS PARA EphA2 | |
| EA202191511A1 (ru) | Составы на основе аналога пептида оксинтомодулина | |
| CL2022003689A1 (es) | Adyuvante con actividad agonista del receptor tipo toll 4 (tlr4) | |
| BR112016011441A2 (pt) | formulação liofilizada, solução aquosa, e, métodos para preparar uma formulação liofilizada e uma solução injetável |